DecisionDx-Melanoma Test Shows Greater Accuracy in Identifying Low-Risk Patients
A prospective study found that Castle Biosciences' DecisionDx-Melanoma i31-SLNB test more accurately identifies melanoma patients who may safely avoid sentinel lymph node biopsy compared to the Melanoma Institute Australia nomogram.